• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1,022
92
66
63
53

COUNTRY

60
20
11
8
6

CATEGORIES

  • 85
  • 124
  • 67
  • 65
  • 37
  • 37
  • 12
  • 12
  • 11
  • 18

PRICE

552
766
1,734
2,753

PUBLISHED

61
96
589
2,753

PRODUCT TYPE

2,645
89
9
6
2
2

Oncology

(2,753 Products)

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

Colorectal Cancer Global Clinical Trials Review, H2, 2013

Colorectal Cancer Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Colorectal Cancer Global Clinical Trials Review, H2, 2013" provides data on the Colorectal Cancer clinical...

November 2013
FROM

Hodgkin Lymphoma Global Clinical Trials Review, H2, 2013

Hodgkin Lymphoma Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Hodgkin Lymphoma Global Clinical Trials Review, H2, 2013" provides data on the Hodgkin Lymphoma clinical...

November 2013
FROM

Thyroid Cancer Global Clinical Trials Review, H2, 2013

Thyroid Cancer Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Thyroid Cancer Global Clinical Trials Review, H2, 2013" provides data on the Thyroid Cancer clinical trial...

November 2013
FROM

Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019

“Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019” The recent approval of a number of highly effective drugs, including...

November 2013
FROM

Renal Disease in Cancer Patients

Renal Disease in Cancer Patients is a translational reference detailing the nephrological problems unique to patients with cancer in an organized and authoritative fashion. This book provides a common...

November 2013
2014 Analysis of the Argentinean Cancer Diagnostics Market: Sales Forecasts, Supplier Shares, Competitive Strategies 2014 Analysis of the Argentinean Cancer Diagnostics Market: Sales Forecasts, Supplier Shares, Competitive Strategies - Product Thumbnail Image

2014 Analysis of the Argentinean Cancer Diagnostics Market: Sales Forecasts, Supplier Shares, Competitive Strategies

2014 Analysis of the Argentinean Cancer Diagnostics Market is a new strategic analysis of the major business opportunities emerging in the Argentinean cancer diagnostics market during the next five...

November 2013
FROM
2014 Analysis of Mexican Cancer Diagnostics Market: Sales Forecasts, Supplier Shares, Competitive Strategies 2014 Analysis of Mexican Cancer Diagnostics Market: Sales Forecasts, Supplier Shares, Competitive Strategies - Product Thumbnail Image

2014 Analysis of Mexican Cancer Diagnostics Market: Sales Forecasts, Supplier Shares, Competitive Strategies

2014 Analysis of Mexican Cancer Diagnostics Market” is a new strategic analysis of the major business opportunities emerging in the Mexican cancer diagnostics market during the next five years The report...

November 2013
FROM

Problem Solving in Acute Oncology

In the United Kingdom there has been increasing attention paid to the needs of cancer patients who present acutely with issues relating to their diagnosis and management, complications of their cancer,...

November 2013

US Lung Cancer Drug Pipeline Analysis

The most common type of cancer in terms of incidence and mortality rate is Lung cancer Lung cancer is a disease in which the lining of the cell of the lung tissue has an uncontrollable growth which...

November 2013
FROM

Global Cancer Monoclonal Antibodies Pipeline Analysis

In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer These monoclonal antibodies are designed to selectively target cancer cells and extract various responses,...

November 2013
FROM

Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth

The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein Four are aimed at improving...

October 2013
FROM

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013',...

October 2013
FROM

Sarcomas - Pipeline Review, H2 2013

Sarcomas - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Sarcomas - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

October 2013
FROM

T-Cell Lymphomas - Pipeline Review, H2 2013

T-Cell Lymphomas - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'T-Cell Lymphomas - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

October 2013
FROM

Burkitt Lymphoma - Pipeline Review, H2 2013

Burkitt Lymphoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Burkitt Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

October 2013
FROM

Glioma - Pipeline Review, H2 2013

Glioma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Glioma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

October 2013
FROM

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2013', provides an overview of...

October 2013
FROM

Neuroendocrine Tumors - Pipeline Review, H2 2013

Neuroendocrine Tumors - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Neuroendocrine Tumors - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Lung Cancer - Pipeline Review, H2 2013

Lung Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Lung Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

October 2013
FROM

Gastrointestinal Tumor - Pipeline Review, H2 2013

Gastrointestinal Tumor - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Gastrointestinal Tumor - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM
Loading Indicator

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)